Author: Vivex Biologics, Inc.

Vivex Biologics’ VIA Disc® NP Meets Primary Endpoint in Pivotal, Sham-Controlled ASCEND Trial Published in Journal of Clinical Medicine

October 28, 2026
Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advanced Wound Care Solutions

July 21, 2026

Vivex Biologics’ VIA Disc® NP Meets Primary Endpoint in Pivotal, Sham-Controlled ASCEND Trial Published in Journal of Clinical Medicine